Published in

Massachusetts Medical Society, New England Journal of Medicine, 23(366), p. 2189-2197

DOI: 10.1056/nejmoa1200966

Elsevier, Year Book of Oncology, (2012), p. 199-200

DOI: 10.1016/j.yonc.2012.08.008

Links

Tools

Export citation

Search in Google Scholar

Combination chemotherapy in advanced adrenocortical carcinoma

Journal article published in 2012 by Martin Fassnacht, S. Wortmann, K. Zopf, H. Wolf, N. Wall, Vincenzo Toscano, Massimo Terzolo, Bruno Allolio, Eric Baudin, C. De La Fouchardiere, Harm Haak, Torpy Dj, Schteingart De, Alfredo Berruti, Staffan Welin and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS: We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. RESULTS: For first-line therapy, patients in the EDP–mitotane group had a significantly higher response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, P